Rocket Total Assets from 2010 to 2024

RCKT Stock

USD 14.39 0.19 1.34%

Rocket Pharmaceuticals Total Assets yearly trend continues to be comparatively stable with very little volatility. Total Assets will likely drop to about 292.8 M in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2013-12-31

Previous Quarter

446.4 M

Current Value

393.7 M

Quarterly Volatility

191.2 M

Yuan Drop

Covid

Check Rocket Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rocket Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.5 M, Interest Expense of 3.3 M or Selling General Administrative of 77 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.37. Rocket financial statements analysis is a perfect complement when working with Rocket Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Rocket Pharmaceuticals Correlation against competitors.

For more information on how to buy Rocket Stock please use our How to Invest in Rocket Pharmaceuticals guide.

Latest Rocket Pharmaceuticals' Total Assets Growth Pattern

Below is the plot of the Total Assets of Rocket Pharmaceuticals over the last few years. Total assets refers to the total amount of Rocket Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Rocket Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Rocket Pharmaceuticals' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Rocket Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 566.34 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Rocket Total Assets Regression Statistics

	Arithmetic Mean	232,639,942
	Geometric Mean	61,981,486
	Coefficient Of Variation	98.63
	Mean Deviation	199,163,672
	Median	129,647,000
	Standard Deviation	229,452,551
	Sample Variance	52648.5T
	Range	589.4M
	R-Value	0.87
	Mean Square Error	13684.7T
	R-Squared	0.76
	Significance	0.000024
	Slope	44,688,489
	Total Sum of Squares	737078.6T

Rocket Total Assets History

	2024	292.8 M
	2023	566.3 M
	2022	551.8 M
	2021	497 M
	2020	590.8 M
	2019	372.1 M
	2018	251.3 M

Other Fundumenentals of Rocket Pharmaceuticals

Intangibles To Total Assets

Rocket Pharmaceuticals Total Assets component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Net Tangible Assets	Long Term Debt	Short Long Term Debt	Short Term Investments	Capital Surpluse	Property Plant Equipment	Long Term Debt Total	Net Invested Capital	Net Working Capital	Long Term Investments	Capital Stock
Total Assets		0.95	-0.24	-0.77	-0.69	0.36	0.63	0.99	0.69	0.89	0.99	0.64	0.01	0.79	0.92	0.75	-0.92	0.97	0.95	0.39	0.83
Total Stockholder Equity	0.95		-0.14	-0.7	-0.81	0.31	0.56	0.94	0.66	0.97	0.96	0.61	-0.14	0.9	0.87	0.86	-0.95	0.97	0.95	0.42	0.87
Current Deferred Revenue	-0.24	-0.14		0.23	0.05	-0.95	-0.03	-0.18	-0.13	-0.09	-0.17	-0.04	-0.17	0.03	-0.24	-0.12	0.11	-0.18	-0.11	-0.49	-0.17
Net Debt	-0.77	-0.7	0.23		0.2	-0.17	-0.33	-0.83	-0.6	-0.54	-0.79	-0.38	0.05	-0.34	-0.62	-0.36	0.6	-0.74	-0.81	0.15	-0.36
Retained Earnings	-0.69	-0.81	0.05	0.2		-0.34	-0.41	-0.62	-0.5	-0.86	-0.69	-0.45	0.2	-0.93	-0.78	-0.95	0.83	-0.75	-0.66	-0.72	-0.94
Accounts Payable	0.36	0.31	-0.95	-0.17	-0.34		0.12	0.27	0.21	0.31	0.29	0.12	0.06	0.24	0.39	0.36	-0.3	0.32	0.22	0.72	0.41
Total Liab	0.63	0.56	-0.03	-0.33	-0.41	0.12		0.63	0.49	0.53	0.58	0.65	0.49	0.58	0.52	0.39	-0.58	0.64	0.64	0.23	0.51
Total Current Assets	0.99	0.94	-0.18	-0.83	-0.62	0.27	0.63		0.67	0.87	0.99	0.67	-0.01	0.75	0.87	0.69	-0.88	0.95	0.95	0.26	0.75
Short Term Debt	0.69	0.66	-0.13	-0.6	-0.5	0.21	0.49	0.67		0.52	0.67	0.1	0.19	0.58	0.78	0.53	-0.74	0.77	0.79	0.24	0.64
Common Stock	0.89	0.97	-0.09	-0.54	-0.86	0.31	0.53	0.87	0.52		0.9	0.62	-0.21	0.95	0.81	0.89	-0.93	0.91	0.87	0.51	0.88
Net Tangible Assets	0.99	0.96	-0.17	-0.79	-0.69	0.29	0.58	0.99	0.67	0.9		0.64	-0.06	0.79	0.91	0.75	-0.92	0.96	0.95	0.34	0.81
Long Term Debt	0.64	0.61	-0.04	-0.38	-0.45	0.12	0.65	0.67	0.1	0.62	0.64		0.18	0.54	0.44	0.43	-0.51	0.55	0.54	0.17	0.43
Short Long Term Debt	0.01	-0.14	-0.17	0.05	0.2	0.06	0.49	-0.01	0.19	-0.21	-0.06	0.18		-0.13	0.07	-0.12	0.02	0.03	0.03	-0.07	-0.06
Short Term Investments	0.79	0.9	0.03	-0.34	-0.93	0.24	0.58	0.75	0.58	0.95	0.79	0.54	-0.13		0.78	0.92	-0.91	0.86	0.81	0.58	0.92
Capital Surpluse	0.92	0.87	-0.24	-0.62	-0.78	0.39	0.52	0.87	0.78	0.81	0.91	0.44	0.07	0.78		0.83	-0.91	0.91	0.86	0.53	0.91
Property Plant Equipment	0.75	0.86	-0.12	-0.36	-0.95	0.36	0.39	0.69	0.53	0.89	0.75	0.43	-0.12	0.92	0.83		-0.88	0.82	0.75	0.63	0.94
Long Term Debt Total	-0.92	-0.95	0.11	0.6	0.83	-0.3	-0.58	-0.88	-0.74	-0.93	-0.92	-0.51	0.02	-0.91	-0.91	-0.88		-0.96	-0.92	-0.5	-0.9
Net Invested Capital	0.97	0.97	-0.18	-0.74	-0.75	0.32	0.64	0.95	0.77	0.91	0.96	0.55	0.03	0.86	0.91	0.82	-0.96		0.99	0.4	0.86
Net Working Capital	0.95	0.95	-0.11	-0.81	-0.66	0.22	0.64	0.95	0.79	0.87	0.95	0.54	0.03	0.81	0.86	0.75	-0.92	0.99		0.24	0.78
Long Term Investments	0.39	0.42	-0.49	0.15	-0.72	0.72	0.23	0.26	0.24	0.51	0.34	0.17	-0.07	0.58	0.53	0.63	-0.5	0.4	0.24		0.73
Capital Stock	0.83	0.87	-0.17	-0.36	-0.94	0.41	0.51	0.75	0.64	0.88	0.81	0.43	-0.06	0.92	0.91	0.94	-0.9	0.86	0.78	0.73

Click cells to compare fundamentals

About Rocket Pharmaceuticals Financial Statements

Rocket Pharmaceuticals shareholders use historical fundamental indicators, such as Total Assets, to determine how well the company is positioned to perform in the future. Although Rocket Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Rocket Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Rocket Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Total Assets	566.3 M	292.8 M
Intangibles To Total Assets	0.11	0.07

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Rocket Stock Analysis

When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC